**Supplementary Table 1: Incidence of all-grade TEAE occurring in ≥5% of patients in Parts A and B.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Part A** | | | | | **Part B** | **Part A + B** | |
| **1 mg/kg weekly (N=3)** | **2 mg/kg weekly (N=3)** | **4 mg/kg weekly (N=6)** | **2 mg/kg load (N=6)** | **4 mg/kg load (N=5)@** | **4 mg/kg load (N=20)#** | **Parts A and B 4 mg/kg load (N=25)$** | **Total (N=43)** |
| **Any Grade CTCAE v4.03 AE** | | | | | | | | |
| Any TEAE | 3 (100.0%) | 3 (100.0%) | 5 (83.3%) | 6 (100.0%) | 5 (100.0%) | 20 (100.0%) | 25 (100.0%) | 42 (97.7%) |
| Any TRX518 related TEAE | 2 (66.7%) | 3 (100.0%) | 3 (50.0%) | 5 (83.3%) | 3 (60.0%) | 12 (60.0%) | 15 (60.0%) | 28 (65.1%) |
| Any SAE | 1 (33.3%) | 0 | 4 (66.7%) | 0 | 2 (40.0%) | 5 (25.0%) | 7 (28.0%) | 12 (27.9%) |
| Any TESAE | 1 (33.3%) | 0 | 4 (66.7%) | 0 | 2 (40.0%) | 5 (25.0%) | 7 (28.0%) | 12 (27.9%) |
| TRX518-related TESAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **AE Summary** | | | | | | | | |
| General:   * Fatigue   Gastrointestinal disorders   * Vomiting * Abdominal pain * Diarrhea   Metabolism and nutrition disorders   * Decreased appetite * Hyponatremia | 1 (33.3%)  1 (33.3%)  0  2 (66.7%)  0  0 | 1 (33.3%)  2 (66.7%)  0  0  1 (33.3%)  0 | 1 (16.7%)  0  1 (16.7%)  0  0  0 | 5 (83.3%)  0  0  0  0  0 | -  -  -  -  -  - | -  -  -  -  -  - | 5 (20.0%)  3 (12.0%)  2 (8.0%)  1 (4.0%)  1 (4.0%)  3 (12.0%) | 13 (30.2%)  6 (14.0%)  3 (7.0%)  3 (7.0%)  2 (4.7%)  3 (7.0%) |
| **CTCAE v4.03 Grades 3-4 AEs** | | | | | | | | |
| Any ≥ Grade 3 TEAE | 1 (33.3%) | 0 | 4 (66.7%) | 2 (33.3%) | 3 (60.0%) | 9 (45.0%) | 12 (48.0%) | 19 (44.2%) |
| TRX518 related ≥grade 3 TEAE | 0 | 0 | 0 | 0 | 0 | 1 (5.0%) | 1 (4.0%) | 1 (2.3%) |
| TRX518 related ≥grade 3 TESAE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any ≥grade 4 TEAE | 0 | 0 | 2 (33.3%) | 1 (16.7%) | 1 (20.0%) | 1 (5.0%) | 2 (8.0%) | 5 (11.6%) |
| Any grade 5 TEAE | 0 | 0 | 0 | 0 | 1 (20.0%) | 0 | 1 (4.0%) | 1 (2.3%) |
| **Reason for Study Discontinuation** | | | | | | | | |
| Death |  | | | | | | 14 (56.0%) | 28 (65.1%) |
| Study terminated by Sponsor | 7 (28.0%) | 7 (16.3%) |
| Withdrawal of ICF | 3 (12.0%) | 7 (16.3%) |
| Other | 1 (4.0%) | 1 (2.3%) |
| @,#,$AEsummary for patients enrolled in 4mg/kg load (Part A)@ (N=5) and 4mg/kg load (Part A)# (N=20) is summarized in Parts A and B 4mg/kg load$.  **Abbreviations:**  CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious adverse event; TEAE, treatment-emergent adverse event; TESAE, treatment-emergent serious adverse event | | | | | | | | |